#### HALOZYME THERAPEUTICS INC

Form 4 April 24, 2007

### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person \* Kelley Kenneth J

Symbol

2. Issuer Name and Ticker or Trading

HALOZYME THERAPEUTICS INC [HTI]

(Month/Day/Year)

04/23/2007

(Middle)

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

**OMB APPROVAL** 

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

**OMB** 

Number:

Expires:

response...

\_X\_\_ Director 10% Owner Other (specify Officer (give title

C/O HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY RD., SUITE 17

(First)

(Street)

(State)

4. If Amendment, Date Original Filed(Month/Day/Year)

3. Date of Earliest Transaction

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

(Zip)

SAN DIEGO, CA 92121

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

|                                      | Table 1 - Non-Delivative Securities Acquired, Disposed bi, of Deficiciany Owner |   |  |        |                  |            |  |   | ly Owned |
|--------------------------------------|---|---|--|--------|------------------|------------|--|---|----------|
| 1.Title of<br>Security<br>(Instr. 3) | 2. Transaction Date (Month/Day/Year)  | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | ecution Date, if Transaction(A) or Disposed of (D)  Code (Instr. 3, 4 and 5) |        |                  | of (D)     | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |          |
| Common                               |   |   | Code V   | Amount | (A)<br>or<br>(D) | Price      | Transaction(s) (Instr. 3 and 4)  |   |          |
| Common<br>Stock                      | 04/23/2007  |   | M <u>(1)</u>   | 25,000 | A                | \$ 4.1     | 40,000   | D   |          |
| Common<br>Stock                      | 04/23/2007  |   | S(1)   | 1,700  | D                | \$<br>8.75 | 38,300   | D   |          |
| Common<br>Stock                      | 04/23/2007  |   | S(1)   | 1,875  | D                | \$<br>8.76 | 36,425   | D   |          |
| Common<br>Stock                      | 04/23/2007  |   | S(1)   | 300    | D                | \$<br>8.77 | 36,125   | D   |          |

### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

| Common<br>Stock | 04/23/2007 | S <u>(1)</u> | 2,000 | D | \$<br>8.78 | 34,125 | D |
|-----------------|------------|--------------|-------|---|------------|--------|---|
| Common<br>Stock | 04/23/2007 | S(1)         | 2,600 | D | \$<br>8.79 | 31,525 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 2,000 | D | \$ 8.8     | 29,525 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 1,825 | D | \$<br>8.81 | 27,700 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 300   | D | \$<br>8.82 | 27,400 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 300   | D | \$<br>8.83 | 27,100 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 1,900 | D | \$<br>8.84 | 25,200 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 2,500 | D | \$<br>8.85 | 22,700 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 1,400 | D | \$<br>8.86 | 21,300 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 600   | D | \$<br>8.87 | 20,700 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 500   | D | \$<br>8.88 | 20,200 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 300   | D | \$ 8.9     | 19,900 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 400   | D | \$<br>8.91 | 19,500 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 400   | D | \$<br>8.92 | 19,100 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 300   | D | \$<br>8.93 | 18,800 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 200   | D | \$<br>8.94 | 18,600 | D |
| Common<br>Stock | 04/23/2007 | S <u>(1)</u> | 1,500 | D | \$<br>8.95 | 17,100 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 300   | D | \$<br>8.96 | 16,800 | D |
| Common<br>Stock | 04/23/2007 | S <u>(1)</u> | 200   | D | \$<br>8.98 | 16,600 | D |
| Common<br>Stock | 04/23/2007 | S(1)         | 200   | D | \$9        | 16,400 | D |
|                 | 04/23/2007 | S(1)         | 800   | D |            | 15,600 | D |

### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

| Common<br>Stock |            |              |     |   | \$<br>9.01        |   |
|-----------------|------------|--------------|-----|---|-------------------|---|
| Common<br>Stock | 04/23/2007 | S(1)         | 100 | D | \$<br>9.03 15,500 | D |
| Common<br>Stock | 04/23/2007 | S <u>(1)</u> |     |   | \$<br>9.05 15,100 | D |
| Common<br>Stock | 04/23/2007 | S <u>(1)</u> | 100 | D | \$ 9.1 15,000     | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | 5. Number of actionDerivative Securities 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |        | erivative Expiration Date eccurities (Month/Day/Year) cquired (A) Disposed of O) nstr. 3, 4, |                    | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |                                     |
|---|---|--------------------------------------|---|--|--|--------|--|--------------------|---|-------------------------------------|
|   |   |                                      |   | Code V                                 | (A)  | (D)    | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of Shares |
| Option to<br>Purchase<br>Common<br>Stock            | \$ 4.1  | 04/23/2007                           |   | M <u>(1)</u>                           |  | 25,000 | 05/21/2004   | 05/21/2014         | Common<br>Stock   | 25,000                              |

# **Reporting Owners**

| Reporting Owner Name / Address   | Relationships |           |         |       |  |  |  |
|--|---------------|-----------|---------|-------|--|--|--|
| and the second of the second o | Director      | 10% Owner | Officer | Other |  |  |  |
| Kelley Kenneth J<br>C/O HALOZYME THERAPEUTICS, INC.<br>11588 SORRENTO VALLEY RD., SUITE 17<br>SAN DIEGO, CA 92121  | X             |           |         |       |  |  |  |
| Signatures   |               |           |         |       |  |  |  |

### Signatures

/s/ Kenneth J. 04/24/2007 Kelley

Reporting Owners 3 \*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares purchased and sold, as applicable, pursuant to 10b5-1 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4